Go Kimura, MD, PhD - Nippon Medical School - Associate Professor

Go Kimura

MD, PhD

Nippon Medical School

Associate Professor

Tokyo | Japan

Main Specialties: Oncology, Urology

Additional Specialties: Urologic pathology

ORCID logohttps://orcid.org/0000-0003-0088-9324

Go Kimura, MD, PhD - Nippon Medical School - Associate Professor

Go Kimura

MD, PhD

Introduction

OFFICE ADDRESS:
Department of Urology, Nippon Medical School,
1-1-5 Sendagi, Bunkyou-ku, Tokyo 113-8603, Japan
Phone: +81-3-3822-2131, Fax: +81-5685-1794
E-mail: gokimura@nms.ac.jp
CITIZENSHIP: JAPAN
MEDICAL LICENSE/LICENSE
Medical License: 1984year
Japanese Board Certified Urologist 1990 year
Japanese Board Certified Instructor 1995 year

EDUCATION AND PROFESSIONAL EXPERIENCE:
1984 Graduate from Nippon Medical School (NMS)
1984 Teaching associate of 1st Department of Pathology, NMS
1985 Clinical fellow, Department of Urology, NMS
1991 Graduate from NMS, Graduate School of Medicine; PhD
Teaching Associate of Department of Urology, NMS
1992-1994 Research fellow, Department of Biology, City of Hope National Medical Center, Duarte, CA. USA
1995-2000 Assistant Professor, Department of Urology, NMS
2000-present Associate Professor, Department of Urology, NMS

Primary Affiliation: Nippon Medical School - Tokyo , Japan

Specialties:

Additional Specialties:

Education

Apr 1991
Nippon Medical School, Graduate School of Medicine
PhD
Mar 1984
Nippon Medical School
MD

Publications

71Publications

1434Reads

26Profile Views

Urothelial Carcinoma of the Bladder, Lipid Cell Variant: Case Report and Literature Review.

J Nippon Med Sch 2020 Jan 15;86(6):349-351. Epub 2019 Jul 15.

Department of Urology, Nippon Medical School.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1272/jnms.JNMS.2019_86-602DOI Listing
January 2020
1 Read
0.588 Impact Factor

Considering bone health in the treatment of prostate cancer bone metastasis based on the results of the ERA-223 trial.

Int J Clin Oncol 2019 12 3;24(12):1629-1631. Epub 2019 Sep 3.

Department of Urology, Kanazawa University, Kanazawa, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-019-01518-7DOI Listing
December 2019
1 Read
2.170 Impact Factor

Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.

Int J Clin Oncol 2019 May 14;24(5):557-566. Epub 2019 Mar 14.

Division of Breast and Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, Japan.

Background: Radium-223 is a first-in-class targeted alpha therapy to prolong overall survival (OS) in castration-resistant prostate cancer with bone metastases (mCRPC). The aim of the present analysis was to assess the long-term safety with radium-223 in Japanese patients with mCRPC.

Methods: Patients with symptomatic mCRPC, ??2 bone metastases and no known visceral metastases received up to 6 injections of radium-223 (55 kBq/kg), one every 4 weeks. Adverse events (AEs) considered to be related to radium-223 were reported until 3 years after the first injection. Pre-specified conditions, such as acute myelogenous leukemia, myelodysplastic syndrome, aplastic anemia, primary bone cancer, or other primary malignancies, were reported regardless of causality.

Results: Of the 49 patients enrolled in the study, 44 (89.8%) entered the survival follow-up period and 33 (67.3%) died. Throughout the entire study, there were no reports of second primary malignancy or other pre-specified conditions. Eight patients (16.3%) experienced post-treatment drug-related AEs, which were all hematological (anemia and decreased lymphocyte, platelet, and white blood cell counts). No serious post-treatment drug-related AEs were reported. Updated median OS was 19.3 months (95% CI: 14.2, 28.5).

Conclusions: In Japanese patients with symptomatic mCRPC and bone metastases, radium-223 had a favorable long-term safety profile with no second primary malignancies reported. Taken together with median OS, which was comparable to that in the pivotal phase III ALSYMPCA study, these results support continued benefit from radium-223 in Japanese patients with mCRPC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-018-01389-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469691PMC
May 2019
6 Reads
2.170 Impact Factor

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

N Engl J Med 2019 03 16;380(12):1116-1127. Epub 2019 Feb 16.

From the Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.); Fox Chase Cancer Center, Philadelphia (E.R.P.); Dnipropetrovsk Medical Academy of Ministry of Health of Ukraine (V.S.) and Dnipropetrovsk Medical Academy (I.B.), Dnipro, Sumy State University, Sumy Regional Oncology Center, Sumy (I.V.), and Ivano-Frankivsk National Medical University, Ivano-Frankivsk (A.K.) - all in Ukraine; the Russian Scientific Center of Roentgen Radiology (R.G.), Central Clinical Hospital with Outpatient Clinic (D.N.), and Hertzen Moscow Cancer Research Institute (B.A.), Moscow; the Christie NHS Foundation Trust, Manchester (R.H.), and Barts Health and the Royal Free NHS Trusts, Barts Cancer Institute, and Queen Mary University of London, London (T.P.) - all in the United Kingdom; Centre Hospitalier Universitaire (CHU) de Québec and Université Laval, Quebec, QC (F.P.), and CHU de Montréal, Montreal (D.S.) - both in Canada; Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (S.J.A.); Centre Antoine Lacassagne, Université Côte d'Azur, Nice (D.B.), and Hôpitaux Universitaires de Lyon, Lyon (S. Tartas) - both in France; Military Institute of Medicine, Warsaw, Poland (C.S.); Rocky Mountain Cancer Center, Colorado Springs, CO (M.M.); Adelaide and Meath Hospital and University College Dublin, Dublin (R.S.M.); the Department of Urology, Eberhard-Karls University Tübingen, Tübingen, Germany (J.B.); Taipei Veterans General Hospital, Taipei, Taiwan (Y.-H.C.); Osaka City University Hospital, Osaka, Japan (S. Tamada); MSD China, Beijing (Q.S.); Merck, Kenilworth, NJ (R.F.P., M.C.); and Georgetown Lombardi Comprehensive Cancer Center, Washington, DC (M.B.A.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1816714DOI Listing
March 2019
11 Reads
55.873 Impact Factor

Atypical pemphigus developed in a patient with urothelial carcinoma treated with nivolumab.

J Dermatol 2019 Mar 31;46(3):e90-e92. Epub 2018 Aug 31.

Department of Dermatology, Nippon Medical School, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1346-8138.14601DOI Listing
March 2019
22 Reads
2.354 Impact Factor

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet Oncol 2019 03 6;20(3):408-419. Epub 2019 Feb 6.

University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Background: Abiraterone acetate plus prednisone or prednisolone improves progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer. Radium-223 improves overall survival and delays the onset of symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases. We assessed concurrent treatment with abiraterone acetate plus prednisone or prednisolone and radium-223 in such patients.

Methods: We did a randomised, double-blind, placebo-controlled, phase 3 trial at 165 oncology and urology centres in 19 countries. Eligible patients were aged 18 years or older, and had histologically confirmed, progressive, chemotherapy-naive, asymptomatic or mildly symptomatic castration-resistant prostate cancer and bone metastases, Eastern Cooperative Oncology Group performance status of 0 or 1, life expectancy of at least 6 months, and adequate haematological, renal, and liver function. Participants were randomly assigned (1:1) according to a permuted block design (block size 4) via interactive response technology to receive up to six intravenous injections of radium-223 (55 kBq/kg) or matching placebo once every 4 weeks. All patients were also scheduled to receive oral abiraterone acetate 1000 mg once daily plus oral prednisone or prednisolone 5 mg twice daily during and after radium-223 or placebo treatment. The primary endpoint was symptomatic skeletal event-free survival, which was assessed in the intention-to-treat population. Safety analyses were done in all patients who received at least one dose of any study drug. This trial is registered with ClinicalTrials.gov, number NCT02043678. Enrolment has been completed, and follow-up is ongoing.

Findings: Between March 30, 2014, and Aug 12, 2016, 806 patients were randomly assigned to receive radium-223 (n=401) or placebo (n=405) in addition to abiraterone acetate plus prednisone or prednisolone. The study was unblinded prematurely, on Nov 17, 2017, after more fractures and deaths were noted in the radium-223 group than in the placebo group (in an unplanned ad-hoc analysis), but all patients had completed radium-223 or placebo before this date. At the primary analysis (data cutoff Feb 15, 2018), 196 (49%) of 401 patients in radium-223 group had had at least one symptomatic skeletal event or died, compared with 190 (47%) of 405 patients in the placebo group (median follow-up 21·2 months [IQR 17·0-25·8]). Median symptomatic skeletal event-free survival was 22·3 months (95% CI 20·4-24·8) in the radium-223 group and 26·0 months (21·8-28·3) in the placebo group (hazard ratio 1·122 [95% CI 0·917-1·374]; p=0·2636). Fractures (any grade) occurred in 112 (29%) of 392 patients in the radium-223 group and 45 (11%) of 394 patients in the placebo group. The most common grade 3-4 treatment-emergent adverse events were hypertension (43 [11%] patients in the radium-223 group vs 52 [13%] patients in the placebo group), fractures (36 [9%] vs 12 [3%]) and increased alanine aminotransferase concentrations (34 [9%] vs 28 [7%]). Serious treatment-emergent adverse events occurred in 160 (41%) patients in the radium-223 group and 155 (39%) in the placebo group. Treatment-related deaths occurred in two (1%) patients in the radium-223 group (acute myocardial infarction and interstitial lung disease) and one (<1%) in the placebo group (arrhythmia).

Interpretation: The addition of radium-223 to abiraterone acetate plus prednisone or prednisolone did not improve symptomatic skeletal event-free survival in patients with castration-resistant prostate cancer and bone metastases, and was associated with an increased frequency of bone fractures compared with placebo. Thus, we do not recommend use of this combination.

Funding: Bayer.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30860-XDOI Listing
March 2019
16 Reads
24.690 Impact Factor

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

N Engl J Med 2018 Apr 21;378(14):1277-1290. Epub 2018 Mar 21.

From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) - both in New York; University of Texas M.D. Anderson Cancer Center, Houston (N.M.T., P. Sharma); Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center (D.F.M.), and Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Harvard Medical School (T.K.C.), Boston; Centro Internacional de Estudios Clínicos (O.A.F.) and Fundación Arturo López Pérez (P. Salman), Santiago, Chile; Palacký University and University Hospital Olomouc, Olomouc, Czech Republic (B.M.); Fox Chase Cancer Center, Philadelphia (E.R.P.); Hôpitaux Universitaires de Strasbourg, Strasbourg (P.B.), Bordeaux University Hospital, Hôpital Saint-André, Bordeaux (A.R.), and Institut Gustave Roussy, Villejuif (B.E.) - all in France; Istituto di Ricovero e Cura a Carattere Scientifico San Matteo University Hospital Foundation, Pavia (C.P.), and Ospedale San Donato, Azienda Unità Sanitaria Locale Toscana Sud-Est, Istituto Toscano Tumori, Arezzo (S.B.) - both in Italy; Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust (T.P.), and Cancer Research UK (R.H.), London; Aarhus University Hospital, Aarhus, Denmark (F.D.); Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, and Tel Aviv University, Tel Aviv - both in Israel (V.N.); British Columbia Cancer Agency, Vancouver, Canada (C.K.K.); Westmead Hospital and Macquarie University, Sydney (H.G.); Jena University Hospital, Jena, Germany (M.-O.G.); Centro de Pesquisa em Oncologia, Hospital São Lucas, Porto Alegre, Brazil (C.H.B.); Niigata University, Niigata, Japan (Y.T.); Hospital Universitario 12 de Octubre, Madrid (D.C.); Cleveland Clinic Taussig Cancer Institute, Cleveland (B.I.R.); Bristol-Myers Squibb, Princeton, NJ (A.C.C., S.M., M.B.M., M.W.-R., J.D.); and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore (H.J.H.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1712126
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1712126DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5972549PMC
April 2018
67 Reads
55.873 Impact Factor

[IV .The Role of Immune Checkpoint Blockade in the Treatment of Bladder Cancer].

Authors:
Go Kimura

Gan To Kagaku Ryoho 2018 Jan;45(1):38-43

Dept. of Urology, Nippon Medical School.

View Article

Download full-text PDF

Source
January 2018
5 Reads

Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer.

Medicine (Baltimore) 2017 Jul;96(27):e7223

aDepartment of Urology, Asan Medical Center, University of Ulsan College of Medicine bDepartment of Urology, Yonsei University College of Medicine cDepartment of Urology, Seoul National University Bundang Hospital dDepartment of Urology, Samsung Medical Center, Seoul, Korea eProstate Center and Division of Urology, Chiba Cancer Center, Chiba fDepartment of Urology, Cancer Institute Hospital of Japanese Foundation for Cancer Research gDepartment of Urology, Showa University Koto Toyosu Hospital, Tokyo, Japan hDepartment of Urology, National University Health System iUrology Centre, Singapore General Hospital, Singapore jMedical Affairs, Medivation, Inc., San Francisco, CA [Medivation was acquired by Pfizer Inc in September 2016] kBiostatistics, Astellas Pharma Europe B.V., Leiden, The Netherlands lDivision of Urology, Cliniques universitaires Saint-Luc, Brussels, Belgium mOHSU Knight Cancer Institute, Oregon Health and Science University, Portland, OR nDepartment of Urology, Nippon Medical School, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000007223DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5502144PMC
July 2017
30 Reads
5.723 Impact Factor

[Transrectal ultrasound in the diagnosis of prostate cancer].

Authors:
Go Kimura

Nihon Rinsho 2016 May;74 Suppl 3:310-7

View Article

Download full-text PDF

Source
May 2016
7 Reads

[Optimization of prostate biopsy strategy in diagnosis of prostate cancer].

Authors:
Go Kimura

Nihon Rinsho 2016 Jan;74(1):79-84

View Article

Download full-text PDF

Source
January 2016
8 Reads

[I. Docetaxel must be reconsidered in light of high cost-effectiveness in the treatment of prostate cancer].

Authors:
Go Kimura

Gan To Kagaku Ryoho 2016 Jan;43(1):45-9

View Article

Download full-text PDF

Source
January 2016
6 Reads

Urothelial carcinoma in a pyelocaliceal diverticulum discovered by magnetic resonance urography.

Int Braz J Urol 2014 Mar-Apr;40(2):274-6

Departments of Urology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/S1677-5538.IBJU.2014.02.19DOI Listing
December 2014
5 Reads
0.956 Impact Factor

Inferior vena cava tumor thrombus after partial nephrectomy for renal cell carcinoma.

BMC Res Notes 2014 Mar 29;7:198. Epub 2014 Mar 29.

Department of Urology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1756-0500-7-198DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3977664PMC
March 2014
28 Reads

Snail expression and outcome in T1 high-grade and T2 bladder cancer: a retrospective immunohistochemical analysis.

BMC Urol 2013 Dec 19;13:73. Epub 2013 Dec 19.

Department of Urology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2490-13-73DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3914703PMC
December 2013
25 Reads
1.937 Impact Factor

Granuloma-forming interstitial pneumonia occurring one year after the start of everolimus therapy.

Intern Med 2013 15;52(2):263-7. Epub 2013 Jan 15.

Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2169/internalmedicine.52.8588DOI Listing
October 2013
15 Reads
0.967 Impact Factor

A case of pneumocystis pneumonia associated with everolimus therapy for renal cell carcinoma.

Jpn J Clin Oncol 2013 May 18;43(5):559-62. Epub 2013 Feb 18.

Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyt019DOI Listing
May 2013
52 Reads
1.747 Impact Factor

Acute renal failure as the presenting sign of disseminated intravascular coagulation in a patient with metastatic prostate cancer.

Int J Nephrol Renovasc Dis 2013 6;6:47-51. Epub 2013 Mar 6.

Division of Diagnostic Pathology, Nippon Medical School, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/IJNRD.S41813DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3595975PMC
March 2013
13 Reads

[Plasmacytoid variant of urothelial carcinoma of urinary bladder: a case report].

Nihon Hinyokika Gakkai Zasshi 2013 Jan;104(1):26-9

The Department of Urology, Nippon Medical School, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5980/jpnjurol.104.26DOI Listing
January 2013
9 Reads

Bone-anchored sling using the Mini Quick Anchor Plus and polypropylene mesh to treat post-radical prostatectomy incontinence: early experience.

Int J Urol 2012 Oct 12;19(10):957-60. Epub 2012 Jul 12.

Department of Urology, Nippon Medical School, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1442-2042.2012.03073.xDOI Listing
October 2012
10 Reads
1.798 Impact Factor

Evaluation of primary prostate cancer using 11C-methionine-PET/CT and 18F-FDG-PET/CT.

Ann Nucl Med 2012 Feb 9;26(2):138-45. Epub 2011 Nov 9.

Department of Radiology, Nippon Medical School, Sendagi, Bunkyo-ku, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12149-011-0551-6DOI Listing
February 2012
8 Reads
1.507 Impact Factor

[Transrectal ultrasound in the diagnosis of prostate cancer].

Authors:
Go Kimura

Nihon Rinsho 2011 Jun;69 Suppl 5:268-74

Department of Urology, Nippon Medical School.

View Article

Download full-text PDF

Source
June 2011
5 Reads

Efficacy of transurethral resection of the bladder tumor (TUR-BT) for huge bladder cancer.

J Nippon Med Sch 2010 Aug;77(4):190-4

Department of Urologic Surgery, Graduate School of Medicine, Nippon Medical School, Bunkyo-ku, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1272/jnms.77.190DOI Listing
August 2010
14 Reads
0.588 Impact Factor

[Case of isolated polyarteritis nodosa appearing in bilateral epididymis].

Nihon Hinyokika Gakkai Zasshi 2010 Mar;101(3):570-3

The Department of Urology, Nippon Medical School, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5980/jpnjurol.101.570DOI Listing
March 2010
10 Reads

Advanced carcinoma of the prostatic urethra in a patient with marked response to chemotherapy, leading to preservation of the bladder.

Int J Clin Oncol 2010 Feb 20;15(1):109-11. Epub 2010 Jan 20.

Department of Urology, Nippon Medical School, Bunkyo-ku, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-009-0006-4DOI Listing
February 2010
15 Reads
2.170 Impact Factor

Relation of leukocytosis in prostatic fluid and inflamed prostatic tissue.

J Nippon Med Sch 2007 Jun;74(3):210-6

Department of Urologic Surgery, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1272/jnms.74.210DOI Listing
June 2007
10 Reads
0.588 Impact Factor

[Testicular metastasis and local recurrence of renal cell carcinoma after nephron-sparing surgery in von Hippel-Lindau disease].

Hinyokika Kiyo 2007 Mar;53(3):163-5

Department of Urology, Kitamurayama Hospital.

View Article

Download full-text PDF

Source
March 2007
7 Reads

Significance of noninvasive diagnosis of prostate cancer with cytologic examination of prostatic fluid.

J Nippon Med Sch 2006 Jun;73(3):129-35

Department of Urology, Second Hospital, Xi'an Jiaotong University, Xi'an, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1272/jnms.73.129DOI Listing
June 2006
20 Reads
0.588 Impact Factor

Study of prostatic fluid from patients with elevated levels of prostate-specific antigen.

J Nippon Med Sch 2006 Feb;73(1):24-8

Department of Urology, Second Hospital, Xi'an Jiaotong University, Xi'an 710004 China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1272/jnms.73.24DOI Listing
February 2006
9 Reads
0.588 Impact Factor

Random systematic sextant biopsy versus power doppler ultrasound-guided target biopsy in the diagnosis of prostate cancer: positive rate and clinicopathological features.

J Nippon Med Sch 2005 Oct;72(5):262-9

Department of Urology, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1272/jnms.72.262DOI Listing
October 2005
6 Reads
0.588 Impact Factor

Luteinizing hormone-releasing hormone agonist monotherapy for prostate cancer: outcome and prognostic factors.

J Nippon Med Sch 2005 Apr;72(2):89-95

Department of Urology, Nippon Medical School, Tokyo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1272/jnms.72.89DOI Listing
April 2005
12 Reads
0.588 Impact Factor

Transitional cell carcinoma of the bladder in four patients on maintenance hemodialysis.

J Nippon Med Sch 2004 Dec;71(6):408-11

Department of Urology, Nippon Medical School, Kanagawa 211-8533, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1272/jnms.71.408DOI Listing
December 2004
5 Reads
0.588 Impact Factor

Detection of urine survivin in 40 patients with bladder cancer.

J Nippon Med Sch 2004 Dec;71(6):379-83

Department of Biochemistry and Cell Biology, Institute of Development and Aging Sciences, Graduate School of Medicine, Nippon Medical School, Tokyo 113-8603, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1272/jnms.71.379DOI Listing
December 2004
10 Reads
0.588 Impact Factor

Laparoscopic radical prostatectomy: initial 30-case experience.

Int J Clin Oncol 2003 Oct;8(5):312-6

Department of Urology, Nippon Medical School, 113-8602, Tokyo, Bunkyo-ku, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10147-003-0345-5DOI Listing
October 2003
7 Reads
2.170 Impact Factor

Expression of cycloxygenase-2 in human bladder and renal cell carcinoma.

Adv Exp Med Biol 2002 ;507:123-6

Kitasato University, School of Pharmaceutical Sciences, Tokyo 108-8641, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4615-0193-0_20DOI Listing
May 2003
9 Reads

[The influence of prostate volume on the diagnostic parameters related to PSA and clinicopathological features of prostate cancer].

Nihon Rinsho 2002 Dec;60 Suppl 11:479-85

Department of Urology, Nippon Medical School.

View Article

Download full-text PDF

Source
December 2002
9 Reads

Top co-authors

Yukihiro Kondo
Yukihiro Kondo

Nippon Medical School

32
Tsutomu Hamasaki
Tsutomu Hamasaki

Nippon Medical School

14
Yasutomo Suzuki
Yasutomo Suzuki

Nippon Medical School

14
Taiji Nishimura
Taiji Nishimura

Nasu Red Cross Hospital

13
Masatoshi Eto
Masatoshi Eto

Kyushu University

10
Hirotsugu Uemura
Hirotsugu Uemura

Kinki University School of Medicine

9
Ichiro Matsuzawa
Ichiro Matsuzawa

Nippon Medical School

8
Nobuo Shinohara
Nobuo Shinohara

Hokkaido University Graduate School of Medicine

8
Jun Akatsuka
Jun Akatsuka

Nippon Medical School

8
Tsunenori Kondo
Tsunenori Kondo

Tokyo Women's Medical University

7